Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study.
Augustin M, Sator PG, von Kiedrowski R, Conrad C, Rigopoulos D, Romanelli M, Ghislain PD, Torres T, Ioannides D, Aassi M, Schulz B, Jagiello P; SERENA study group. Augustin M, et al. Among authors: sator pg. J Eur Acad Dermatol Venereol. 2022 Oct;36(10):1796-1804. doi: 10.1111/jdv.18329. Epub 2022 Jul 4. J Eur Acad Dermatol Venereol. 2022. PMID: 35696305
Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study.
Klein TM, Blome C, Kleyn CE, Conrad C, Sator PG, Ståhle M, Eyerich K, Radtke MA, Bundy C, Cordey M, Griffiths CEM, Augustin M. Klein TM, et al. Among authors: sator pg. Dermatol Ther (Heidelb). 2022 Jan;12(1):81-95. doi: 10.1007/s13555-021-00628-3. Epub 2021 Nov 23. Dermatol Ther (Heidelb). 2022. PMID: 34813044 Free PMC article.
Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysis.
Graier T, Weger W, Sator PG, Salmhofer W, Gruber B, Jonak C, Kölli C, Schütz-Bergmayr M, Vujic I, Ratzinger G, Häring N, Painsi C, Prillinger K, Mlynek A, Skvara H, Trattner H, Tanew A, Lichem R, Ellersdorfer C, Legat F, Gruber-Wackernagel A, Hofer A, Schmiedberger E, Hoetzenecker W, Müllegger R, Saxinger W, Quehenberger F, Wolf P. Graier T, et al. Among authors: sator pg. JAAD Int. 2020 Dec 26;2:62-75. doi: 10.1016/j.jdin.2020.10.012. eCollection 2021 Mar. JAAD Int. 2020. PMID: 34409355 Free PMC article.
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations.
Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Csörgö Z, Boonen H, De Jong E, Garcia-Doval I, Gisondi P, Kaur-Knudsen D, Mahil S, Mälkönen T, Maul JT, Mburu S, Mrowietz U, Reich K, Remenyik E, Rønholt KM, Sator PG, Schmitt-Egenolf M, Sikora M, Strömer K, Sundnes O, Trigos D, Van Der Kraaij G, Yawalkar N, Dressler C. Nast A, et al. Among authors: sator pg. J Eur Acad Dermatol Venereol. 2021 Feb;35(2):281-317. doi: 10.1111/jdv.16926. J Eur Acad Dermatol Venereol. 2021. PMID: 33547728 Free article.
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations.
Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Csörgö Z, Boonen H, De Jong E, Garcia-Doval I, Gisondi P, Kaur-Knudsen D, Mahil S, Mälkönen T, Maul JT, Mburu S, Mrowietz U, Reich K, Remenyik E, Rønholt KM, Sator PG, Schmitt-Egenolf M, Sikora M, Strömer K, Sundnes O, Trigos D, Van Der Kraaij G, Yawalkar N, Dressler C. Nast A, et al. Among authors: sator pg. J Eur Acad Dermatol Venereol. 2020 Nov;34(11):2461-2498. doi: 10.1111/jdv.16915. J Eur Acad Dermatol Venereol. 2020. PMID: 33349983
Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis.
Graier T, Salmhofer W, Jonak C, Weger W, Kölli C, Gruber B, Sator PG, Prillinger K, Mlynek A, Schütz-Bergmayr M, Richter L, Ratzinger G, Painsi C, Selhofer S, Häring N, Wippel-Slupetzky K, Skvara H, Trattner H, Tanew A, Inzinger M, Tatarski R, Bangert C, Ellersdorfer C, Lichem R, Gruber-Wackernagel A, Hofer A, Legat F, Schmiedberger E, Strohal R, Lange-Asschenfeldt B, Schmuth M, Vujic I, Hoetzenecker W, Trautinger F, Saxinger W, Müllegger R, Quehenberger F, Wolf P. Graier T, et al. Among authors: sator pg. Br J Dermatol. 2021 Jun;184(6):1094-1105. doi: 10.1111/bjd.19701. Epub 2021 Feb 22. Br J Dermatol. 2021. PMID: 33289075 Free PMC article.
Short- and long-term efficacy of fumaric acid esters or acitretin in combination with a 12-week course of PUVA in the treatment of palmoplantar pustulosis: results from a prospective randomized trial.
Aichelburg MC, Pinkowicz A, Holzer G, Radakovic S, Sator PG, Tanew A. Aichelburg MC, et al. Among authors: sator pg. J Eur Acad Dermatol Venereol. 2021 Mar;35(3):e198-e200. doi: 10.1111/jdv.16909. Epub 2020 Oct 1. J Eur Acad Dermatol Venereol. 2021. PMID: 32869392 Clinical Trial. No abstract available.
Quality of Life, Anxiety, and Depression in Patients With Early-Stage Mycosis Fungoides and the Effect of Oral Psoralen Plus UV-A (PUVA) Photochemotherapy on it.
Graier T, Fink-Puches R, Porkert S, Lang R, Pöchlauer S, Ratzinger G, Tanew A, Selhofer S, Sator PG, Hofer A, Gruber-Wackernagel A, Legat FJ, Vieyra-Garcia PA, Quehenberger F, Wolf P. Graier T, et al. Among authors: sator pg. Front Med (Lausanne). 2020 Aug 5;7:330. doi: 10.3389/fmed.2020.00330. eCollection 2020. Front Med (Lausanne). 2020. PMID: 32850876 Free PMC article.
36 results